Investigational drug · Phase 2
AGN-151607-DP
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ventral Hernia, Upper Limb Essential Tremor.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "AGN-151607-DP"
First trial start
2026
Feb 4, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AGN-151607-DP", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ventral Hernia
- Upper Limb Essential Tremor
Largest trials
Live from ClinicalTrials.gov: studies naming "AGN-151607-DP" as an intervention, largest first.
- Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia RepairPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07226791 · 200 participants (planned) · Start Feb 4, 2026 · Primary completion Sep 2028
Drug: AGN-151607-DP; Placebo for AGN-151607-DP · For: Ventral Hernia
Sites: Riverside, California; Jacksonville, Florida; Miami, Florida · 13 sites in all
AbbVieAbbVie (ABBV)
NCT07673107 · 94 participants (planned) · Start Jun 23, 2026 · Primary completion Nov 2028
Drug: AGN-151607-DP; Placebo for AGN-151607-DP · For: Upper Limb Essential Tremor
Sites: Carlsbad, California; Fresno, California; Fullerton, California · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.